

## NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

## DATA SHEET

| Reagent:                | Bevirimat Dimeglumine   |
|-------------------------|---|
| Catalog Number:         | 12199   |
| Lot Number:             | 120080  |
| Release Category:       | A   |
| Provided:               | 30mg  |
| Chemical Name:          | 3-O-(3',3' -dimethylsuccinyl) betulinic acid di-N-methyl-D-glucamine salt                         |
| Empirical<br>Formula:   | C <sub>36</sub> H <sub>56</sub> O <sub>6</sub> 2(C <sub>7</sub> H <sub>17</sub> NO <sub>5</sub> ) |
| HPLC Purity:            | 98.4% (by HPLC)   |
| Molecular Weight:       | 975.28  |
| CAS Num:                | 823821-85-8   |
| Solubility:             | Methanol >30mg/ml<br>Water insoluble  |
| Mechanical<br>Action:   | HIV viral maturation inhibitor  |
| Recommended<br>Storage: | Room Temperature  |
| Contributor:            | Myrexis, Inc.   |

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

| References:  | Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60.  |
|--------------|---|
|              | Zhou J, Huang L, Hachey DL, Chen CH, Aiken C. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles.J Biol Chem. 2005 Dec 23;280(51):42149-55.   |
|              | Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.Determinants of activity of the HIV-1 maturation inhibitor PA-457.Virology. 2006 Dec 5-20;356(1-2):217-24.  |
|              | Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. |
| NOTE:        | Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, NIAID, NIH and Myrexis, Inc: Bevirimat".  |
| Last Updated | July 24, 2018   |

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.